News

Recent research highlights the understudied role of cytokines in various subtypes of cutaneous lupus erythematosus, primarily that cytokines interleukin-1 (IL-1-beta), interleukin-17 (IL-17) and tumor necrosis factor-alpha (TNF-alpha) are involved in the pathogenesis of the disease. These results were recently presented at the 74th Annual Meeting of the American Academy of Dermatology…

GSK has published a new analysis showing that moderate-to-severe systemic lupus erythematosus (SLE) patients treated for five years with Benlysta (belimumab), in combination with standard of care, demonstrated low rates of progression in organ damage regardless of their condition prior to starting therapy.

Clinical management of systemic lupus erythematosus (SLE) is challenging, and aims mainly to slow or prevent organ damage, particularly kidney injury. A review, publisThed in the journal ImmunoTargets and Therapy, shows that while immunosuppressive and biological agents form the basis of disease control in lupus, clinicians need…

Pulmonary arterial hypertension (PAH) is a prevalent comorbid factor in systemic lupus erythematosus (SLE) patients, significantly increasing mortality outcomes. This is the conclusion of a recent review titled “Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis,” published in the journal…

Xencor announced the beginning of two Phase 2 clinical trials testing its drug candidate, XmAb5871, to treat systemic lupus erythematosus (SLE) and IgG4-related disease (IgG4-RD), a rare fibro-inflammatory autoimmune disorder. In both trials, a first patient has already received an initial testing dose. XmAb5871 is a monoclonal antibody that targets both CD19 and the FcγRIIb…

ImmuPharma PLC announced that Phase 3 clinical studies evaluating the safety and efficacy of Lupuzor — its lead compound to treat lupus – are now getting underway and enrolling patients in Europe, and continuing to enroll people in the U.S., where first dosing has already begun. The pivotal trial, titled “A 52-Week,…

The excessive inflammatory response that is characteristic of systemic lupus erythematosus (SLE) has now been shown by scientists at University College London to be caused by altered signaling between different kinds of immune cells — leading to a lack of production of regulatory B-cells to control immune responses. The team studied three different immune cells…

Corbus Pharmaceuticals Holdings, Inc., announced it will soon begin a Phase 2 clinical trial to test the efficacy, safety, tolerability, and biologic effects of its drug candidate, Resunab, in patients with systemic lupus erythematosus (SLE). Resunab is a first-in-class, synthetic oral endocannabinoid-mimetic drug that preferentially binds to the CB2 receptor expressed on activated…

A nutritious diet likely helps protects against lupus flare-ups, but contrary to what other studies have indicated, Vitamin D does not seem to make a difference, according to Ph.D. student Cecilia Lourdudoss of Sweden’s Karolinska Institutet. She recently spoke to The Lupus Foundation of America about her study of diet and glucosteroid…

Israel-based XTL Biopharmaceuticals, a clinical stage biotech company that focuses on the development of new drugs for the treatment of autoimmune diseases, has announced that its lead drug candidate, hCDR1, has been granted a patent by the Hungarian Intellectual Property Office. The patent, “Synthetic Human Peptides and Pharmaceutical Compositions Comprising…